Cencora, Inc.: directors' dealings · United States · SEC (Form 4)

About Cencora, Inc.

Cencora, Inc. (NYSE: COR) is a major healthcare infrastructure and pharmaceutical distribution company based in Conshohocken, Pennsylvania, United States. Formerly known as AmerisourceBergen, the company rebranded as Cencora to better reflect its expanding global footprint and its central role in improving access to medicines across the healthcare supply chain. For international equity investors, Cencora is best understood not as a traditional drug manufacturer, but as a critical intermediary and service platform connecting pharmaceutical manufacturers, healthcare providers, pharmacies, and specialty practices. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2023/AmerisourceBergen-becomes-Cencora-in-alignment-with-the-companys-growing-global-footprint-and-central-role-in-pharmaceutical-access-and-care/default.aspx?utm_source=openai)) The company reports two principal segments: U.S. Healthcare Solutions and International Healthcare Solutions, with certain businesses grouped in Other. Its core business remains wholesale pharmaceutical distribution, but Cencora has steadily expanded into higher-value services that support the commercialization and delivery of complex therapies. These include specialty distribution, patient and provider support services, logistics integration, data and analytics, and services for physician practices and care networks. This mix gives Cencora exposure to faster-growing areas of healthcare, particularly specialty care, oncology, ophthalmology, and advanced therapies. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-First-Quarter-Results/default.aspx?utm_source=openai)) In competitive terms, Cencora holds a strong scale position in U.S. pharmaceutical distribution, an industry defined by high regulatory, logistical, and technology barriers. The company emphasizes its ability to improve product access, traceability, inventory resilience, and supply-chain efficiency. At the same time, management is actively broadening the platform through targeted investments in specialty healthcare. In 2025, Cencora completed the acquisition of Retina Consultants of America (RCA), strengthening its specialty management services platform. The company also announced plans to invest about $1 billion through 2030 to expand and harden its U.S. distribution network, including added capacity and improved resilience. ([cencora.com](https://www.cencora.com/newsroom/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america?utm_source=openai)) Recent developments underline this strategy. In 2025, Cencora reported growth in revenue and adjusted earnings, supported by underlying market expansion and acquisition-driven contributions. In 2026, the company announced acceleration of its OneOncology investment and a transaction involving MWI Animal Health and Covetrus, further reinforcing its specialty and animal-health platforms. Taken together, these moves point to a company pursuing a balanced strategy: defend its scale leadership in pharmaceutical distribution while building a broader, higher-margin services ecosystem around specialty care. For long-term investors, that combination offers a defensive healthcare profile with structural growth opportunities tied to the complexity of modern care delivery. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2025/Cencora-Accelerates-OneOncology-Acquisition-Extending-Solutions-Offering-for-Community-Oncology/default.aspx?utm_source=openai))